Marrow extracts $120M series B to advance preclinical blood disease therapy

An artist's depiction of different types of blood cells from bone marrow
“The major challenge in targeting bone marrow has been the risk of anemia,” Marrow CEO Romesh Subramanian told Fierce. “We have cracked that nut.” (Getty Images)

A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in overall funding and a preclinical lead program aimed at sickle cell disease and beta thalassemia.

Having already secured $54 million from a series A led by its founder Scion Life Sciences and venBio, Marrow has strengthened its financial backbone courtesy of a $120 million series B led by OrbiMed. The biotech’s lead candidate, dubbed MAR-101, uses the company’s in vivo transferrin antibody bioconjugate platform to reduce the blood cell development protein BCL11A, which underlies both target diseases.

“While many companies have pursued transferrin receptor-targeted approaches, the major challenge in targeting bone marrow has been the risk of anemia, which limited earlier treatment options,” Marrow CEO Romesh Subramanian, Ph.D., told Fierce via email. “We have cracked that nut.”

Subramanian—who previously helmed Ascidian Therapeutics and Dyne Therapeutics—also noted that Marrow's platform can accommodate multiple payload types to expand into a range of hematologic diseases.

In preclinical IND-enabling studies, MAR-101 has shown BCL11A knockdown and activity comparable to or better than ex vivo approaches, the CEO said. Marrow has also built a “remarkably robust” safety profile around the candidate, which Subramanian said is “a key differentiator we believe will translate to the clinic, potentially positioning us to explore a wider range of doses and treatment regimens for patients compared to earlier genetic medicine approaches.”

Gene therapies in the hematologic space include Vertex and CRISPR Therapeutics’ Casgevy for sickle cell and beta thalassemia, bluebird bio’s Lyfgenia for sickle cell and bluebird’s Zynteglo for beta thalassemia.

But gene therapies come with challenges that include conditioning requirements, manufacturing costs and infrastructure needs that Subramanian said Marrow intends to address with a more accessible option.

“Our in vivo approach [has] the potential to deliver disease-modifying genetic medicines through a more convenient, scalable and accessible model, with an ultimate goal of reaching patients globally—in the U.S. and EU and in regions such as sub-Saharan Africa, the Middle East and Southeast Asia, where sickle cell disease and other serious blood disorders represent a significant burden,” Subramanian said.